Pencho P. Genov

UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Pencho P. Genov et autres

PURPOSE: We report the duration of response to UGN-102 treatment in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) 24 months after achieving complete response (CR). MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with …

us, bg (code pays fourni par la source)

Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.

Sandip M. Prasad, Marc A. Bjurlin, Dimitar Shishkov, Nikola Vladimirov Mihaylov et autres

e16595 Background: In the ATLAS and ENVISION phase 3 studies (NCT04688931/NCT05243550) patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) were treated with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously reported for the individual studies; …

us, bg (code pays fourni par la source)

Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.

Sandip M. Prasad, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze, Pencho P. Genov et autres

4598 Background: Low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a recurrent cancer inadequately controlled by the current standard of care: transurethral resection of bladder tumor (TURBT). ENVISION (NCT05243550), is an ongoing prospective, phase 3, multinational, single-arm trial, evaluating UGN-102 in patients …

us, bg (code pays fourni par la source)

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

John P. Sfakianos, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze et autres

4597 Background: In the ENVISION pivotal phase 3 study (NCT05243550) patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) were treated with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously reported. Complete response rate (CRR) at …

us, bg (code pays fourni par la source)

PD12-01 TREATMENT OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH UGN-102: ONGOING RESULTS FROM A SINGLE-ARM, OPEN-LABEL, PHASE 3 TRIAL (ENVISION)

Sandip M. Prasad, Dimitar Shishkov, Nikola Vmihaylov, Alexandre Vkhuskivadze et autres

PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH UGN-102: A SINGLE-ARM, OPEN-LABEL, PHASE 3 TRIAL (ENVISION)

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze et autres

us (code pays fourni par la source)

Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.

Sandip M. Prasad, Brian Robin Hu, Marc A. Bjurlin, Dimitar Shishkov et autres

777 Background: The ATLAS and ENVISION phase 3 studies (NCT04688931/NCT05243550) treated patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously reported for the individual studies; here we report …

us, bg (code pays fourni par la source)

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze et autres

776 Background: The ENVISION phase 3 study (NCT05243550) treated patients withlow-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously reported. Complete response (CR) rate at 3 months was 79.6%, with …

us, bg (code pays fourni par la source)

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze et autres

PURPOSE: We evaluate the efficacy and safety of UGN-102 chemoablation for the primary treatment of patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with a biopsy-proven recurrence of …

us, bg (code pays fourni par la source)

Use of micromeshed split thickness skin graft for penile skin reconstruction

Vladislav Rosenov Dunev, B.A. Stoykov, Jitian A. Atanasov, S.K. Velichkov et autres

We review a case of total penile skin replacement with split-thickness micromesh skin graft (micromesh STSG) due to paraffinoma.

bg (code pays fourni par la source)

TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NONMUSCLE-INVASIVE BLADDER CANCER WITH UGN-102 ± TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) COMPARED TO TURBT MONOTHERAPY: THE PHASE 3 ATLAS TRIAL

Sandip M. Prasad, William C. W. Huang, Neal D. Shore, Brian Robin Hu et autres

us, bg, ru (code pays fourni par la source)

A RARE CASE OF LEIOMYOSARCOMA OF PENIS

Pencho P. Genov, Ivan VELEV, Eva CONKOVA, Ivanichka Serbezova et autres

Un cas rare de léiomyosarcome du pénisIntroduction.Les tumeurs mésenchymateuses du pénis sont extrêmement rares et parmi elles, les sarcomes sont exceptionnels.Moins de 100 cas de léiomyosarcomes ont été rapportés dans la littérature anglophone.Rapport du cas.Nous rapportons un patient présentant une tumeur dans …

bg (code pays fourni par la source)